mbiomics, a Bavaria-based BioTech startup advancing scalable microbiome-based therapeutics for severe and chronic diseases, has announced the third closing of its Series A round at €12 million, bringing the total round size to €30 million.
The round includes participation from existing investors, including MIG Fonds and Bayern Kapital. According to the company, this financing marks its transition from platform building into clinical execution, as it advances its platform into scalable manufacturing and clinical translation.
“While the clinical potential of the gut microbiome is well understood, transforming microbiome-based therapeutics into a scalable product has remained a significant engineering challenge. At mbiomics, we are solving this challenge by building the full technology stack for the design, analysis, screening, and manufacturing of complex microbial consortia. We are now focapplyd on advancing our lead candidate, MBX-116, towards clinical evaluation,” stated Dr Johannes B. Woehrstein, CEO and co-founder of mbiomics.
Founded in 2020 by Dr Johannes Wöhrstein, Dr Markus Rinecker, and Dr Laura Figulla, mbiomics’s goal is to access the gut microbiome’s full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease.
It designs and develops complex microbiome-based therapeutics for the treatment of severe and chronic diseases. It brings toreceiveher proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities to achieve indication-specific activity and address patient heterogeneity.
The company develops Live Biotherapeutic Products (LBPs), which are oral therapeutics composed of live bacterial strains. These products are designed to restore the functional and metabolic potential of the gut microbiome in a scalable, pharmaceutical-grade format.
mbiomics states that Faecal Microbiota Transplants (FMTs) have demonstrated clinical efficacy across multiple indications and validated microbiome modulation as a therapeutic strategy. This approach is inherently variable and non-scalable.
“By contrast, mbiomics’ proprietary platform enables the rational design of defined, large, and complex microbial consortia. The platform combines AI/ML-driven consortia design, proprietary analytical technology, large consortium co-cultivation, and screening capabilities,” explained the company.
The BioTech startup also notes that in oncology, clinical evidence has displayn that modulating the gut microbiome can significantly enhance response rates to immune checkpoint inhibitors.
Based on this rationale, mbiomics is initially focutilizing on second-line melanoma to evaluate the potential of its lead candidate MBX-116, as a co-therapy. The goal is to improve treatment outcomes in this setting, with the start of a Phase 1B study planned for 2027.
Dr Matthias Kromayer, Managing Partner of MIG Capital, stated, “We are pleased to continue our support of mbiomics in this financing round. Since our initial investment, the team has built impressive progress in translating microbiome science into a scalable therapeutic approach. The company is heading into clinical validation and continuing to build its broader therapeutic pipeline with great momentum.”
With the fresh capital, the company plans to further strengthen the IND-enabling pharmacological data sets and to accelerate GMP development and manufacturing. This funding comes as mbiomics prepares for the clinical evaluation of its lead candidate, MBX-116, as an immune checkpoint inhibitor co-therapy in advanced melanoma.
Beyond oncology, the company is advancing a broader pipeline of microbiome-based therapeutics. mbiomics expects that this pipeline could support expansion into additional indications where the gut microbiome plays a central role, such as autoimmune and neurodegenerative diseases.
Leave a Reply